相似文献
1
Therapeutic targeting of the functionally elusive TAM receptor family.
Nat Rev Drug Discov. 2024 Mar;23(3):201-217. doi: 10.1038/s41573-023-00846-8. Epub 2023 Dec 13.
2
TAM family kinases as therapeutic targets at the interface of cancer and immunity.
Nat Rev Clin Oncol. 2023 Nov;20(11):755-779. doi: 10.1038/s41571-023-00813-7. Epub 2023 Sep 4.
3
TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
Cancer Immunol Immunother. 2020 Feb;69(2):237-244. doi: 10.1007/s00262-019-02421-w. Epub 2019 Oct 29.
4
Phosphatidylserine Sensing by TAM Receptors Regulates AKT-Dependent Chemoresistance and PD-L1 Expression.
Mol Cancer Res. 2017 Jun;15(6):753-764. doi: 10.1158/1541-7786.MCR-16-0350. Epub 2017 Feb 9.
5
Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
Mol Cancer. 2019 May 14;18(1):94. doi: 10.1186/s12943-019-1022-2.
6
Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders.
Front Immunol. 2023 Jul 20;14:1135373. doi: 10.3389/fimmu.2023.1135373. eCollection 2023.
7
Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
Cancer Res. 2021 Feb 1;81(3):698-712. doi: 10.1158/0008-5472.CAN-20-2066. Epub 2020 Nov 25.
8
TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.
Br J Cancer. 2019 Mar;120(5):555-564. doi: 10.1038/s41416-019-0397-6. Epub 2019 Feb 15.
9
Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity.
Sci Rep. 2017 Mar 8;7:43908. doi: 10.1038/srep43908.
10
Recent advances in TAM mechanisms in lung diseases.
J Transl Med. 2025 Apr 26;23(1):479. doi: 10.1186/s12967-025-06398-2.
引用本文的文献
1
Bioengineered hybrid dual-targeting nanoparticles reprogram the tumour microenvironment for deep glioblastoma photodynamic therapy.
Nat Commun. 2025 Aug 18;16(1):7672. doi: 10.1038/s41467-025-63081-2.
2
Inhibition of Axl attenuates acute kidney injury by alleviating inflammation via SOCS3 downregulation in tubular epithelial cells.
BMC Nephrol. 2025 Jul 1;26(1):325. doi: 10.1186/s12882-025-04222-z.
3
Expression pattern and clinical significance of MerTK on circulating NK cells in systemic lupus erythematosus.
Lupus Sci Med. 2025 Jun 19;12(1):e001407. doi: 10.1136/lupus-2024-001407.
4
Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody-drug conjugate.
Antib Ther. 2025 Apr 10;8(2):145-156. doi: 10.1093/abt/tbaf006. eCollection 2025 Apr.
5
Inhibitory effect on endometrial cancer: Collagen type XII α1 chain.
Cytojournal. 2025 Mar 12;22:31. doi: 10.25259/Cytojournal_236_2024. eCollection 2025.
6
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.
Future Oncol. 2025 May;21(11):1349-1356. doi: 10.1080/14796694.2025.2485015. Epub 2025 Apr 18.
7
Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us?
Cell Death Dis. 2025 Mar 5;16(1):155. doi: 10.1038/s41419-025-07480-9.
8
MERTK inhibition improves therapeutic efficacy of immune checkpoint inhibitors in hepatocellular carcinoma.
Oncoimmunology. 2025 Dec;14(1):2473165. doi: 10.1080/2162402X.2025.2473165. Epub 2025 Mar 3.
9
AXL signaling in cancer: from molecular insights to targeted therapies.
Signal Transduct Target Ther. 2025 Feb 10;10(1):37. doi: 10.1038/s41392-024-02121-7.
10
Targeting AXL Inhibits the Growth and Metastasis of Prostate Cancer in Bone.
Clin Cancer Res. 2025 Apr 1;31(7):1346-1358. doi: 10.1158/1078-0432.CCR-24-3028.
本文引用的文献
1
Tissue-specific modifier alleles determine loss-of-function traits.
Elife. 2022 Aug 15;11:e80530. doi: 10.7554/eLife.80530.
2
Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
Mol Cancer Ther. 2022 Apr 1;21(4):582-593. doi: 10.1158/1535-7163.MCT-21-0715.
3
Gas6/TAM Signalling Negatively Regulates Inflammatory Induction of GM-CSF in Mouse Brain Microglia.
Cells. 2021 Nov 24;10(12):3281. doi: 10.3390/cells10123281.
4
AXL receptor is required for Zika virus strain MR-766 infection in human glioblastoma cell lines.
Mol Ther Oncolytics. 2021 Nov 11;23:447-457. doi: 10.1016/j.omto.2021.11.001. eCollection 2021 Dec 17.
5
Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer.
Cancers (Basel). 2021 Nov 23;13(23):5877. doi: 10.3390/cancers13235877.
6
Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer.
Cancers (Basel). 2021 Nov 11;13(22):5639. doi: 10.3390/cancers13225639.
7
Phosphatidylserine receptors enhance SARS-CoV-2 infection.
PLoS Pathog. 2021 Nov 19;17(11):e1009743. doi: 10.1371/journal.ppat.1009743. eCollection 2021 Nov.
8
Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
Mol Cancer Res. 2022 Mar 1;20(3):446-455. doi: 10.1158/1541-7786.MCR-21-0444.
9
AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill -ITD acute myeloid leukemia.
Haematologica. 2022 Jun 1;107(6):1311-1322. doi: 10.3324/haematol.2021.278369.
10
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.
Mol Cancer Res. 2022 Feb;20(2):265-279. doi: 10.1158/1541-7786.MCR-21-0302. Epub 2021 Oct 20.
Zotero 插件